Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 13, 2020

View Archived Issues

In AML, collapse prevents relapse

Notable responses seen in COVID-19 patients with respiratory failure given RLF-100

Daiichi Sankyo describes new SIRT6 activators

G protein-coupled receptor 35 modulators discovered at Precision IBD

Novartis presents NLRP3 inflammasome inhibitors

Merck KGaA discovers dual adenosine A2A/A2B receptor antagonists

Discovery and preclinical evaluation of anticancer agent, PVHD-303

First-in-human data presented for [68Ga]P15-041 radiotracer

Yumanity Therapeutics identifies stearoyl-CoA desaturase 1/5 inhibitors

VBL announces second successful pre-planned interim analysis of the phase III OVAL study

First patient enrolled in phase III InPedILD study of nintedanib

FDA approves Viltepso for the treatment of DMD in patients amenable to exon 53 skipping therapy

First phase I study of ATG-017 approved in Australia

Recombinant SARS-CoV-2 S1-Fc fusion protein shows promise in animal species

Treadwell initiates phase II study of CFI-400945 and durvalumab in TNBC

TREM2 targeting can synergize with checkpoint blockade

Phase I study results support further evaluation of yellow fever monoclonal antibody TY-014

Bio-Path begins dosing in amended stage 2 of phase II prexigebersen study in AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...